ReviewDiagnostics (Basel, Switzerland)2022
Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.Clinical pharmacokinetics · 2026Article
- Advancements in Cardiac Magnetic Resonance Imaging: Innovations, Challenges, and Future Directions.Reviews in cardiovascular medicine · 2026Review
- Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).Chinese neurosurgical journal · 2026Review
- Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.Pediatric radiology · 2026Review
- The evaluation of non-contrast MRA using a modified balanced steady state free precession technique in the follow-up of renal artery aneurysm after embolotherapy.Abdominal radiology (New York) · 2026Article
- Knowledge-Guided Framework for Synthesizing Contrast-Dependent Data from Multi-Sequence Non-Contrast MRI.Diagnostics (Basel, Switzerland) · 2026Article
- Purification and pharmacokinetic study of gadoxetate isomers for enhanced rabbit liver MR imaging.PloS one · 2026Article
- Superparamagnetic iron oxide nanoparticles in clinical applications: current status and future perspectives.EBioMedicine · 2025Review
- Monitoring Pharmacological Treatment of Breast Cancer with MRI.Current issues in molecular biology · 2025Review
- The Skin: A Critical Window into Chronic Kidney Disease and a Call for Collaborative Care.Journal of multidisciplinary healthcare · 2025Article
- Non-contrast-enhanced magnetic resonance urography for measuring split kidney function in pediatric patients with hydronephrosis: comparison with renal scintigraphy.Pediatric nephrology (Berlin, Germany) · 2024Article
- AI-powered contrast-free cardiovascular magnetic resonance imaging for myocardial infarction.Frontiers in cardiovascular medicine · 2024Review
- Peripheral arterial disease treatment planning using noninvasive and invasive imaging methods.Journal of vascular surgery cases and innovative techniques · 2023Article
- Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.Nature reviews. Endocrinology · 2023Review
- Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review.European journal of radiology open · 2023Review
- The Multi-Faceted Utility of Cardiovascular Magnetic Resonance Imaging: Editorial on Special Issue "Advances in Cardiovascular Magnetic Resonance".Diagnostics (Basel, Switzerland) · 2023Article
- Yeast Deletomics to Uncover Gadolinium Toxicity Targets and Resistance Mechanisms.Microorganisms · 2023Article
- Cardiac magnetic resonance assessment of cardiac involvement in autoimmune diseases.Frontiers in cardiovascular medicine · 2023Review
- The complex role of cardiovascular imaging in viability testing.Progress in cardiovascular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadolinium-enhanced cardiac magnetic resonance has revolutionized cardiac imaging in the last two decades and has emerged as an essential and powerful tool for the characterization and treatment guidance of a wide range of cardiovascular diseases. However, due to the high prevalence of chronic renal dysfunction in patients with cardiovascular conditions, the risk of nephrogenic systemic fibrosis (NSF) after gadolinium exposure has been a permanent concern. Even though the newer macrocyclic agents have proven to be much safer in patients with chronic kidney disease and end-stage renal failure, clinicians must fully understand the clinical characteristics and risk factors of this devastating pathology and maintain a high degree of suspicion to prevent and recognize it. This review aimed to summarize the existing evidence regarding the physiopathology, clinical manifestations, diagnosis, and prevention of NSF related to the use of gadolinium-based contrast agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.